

NIH AIDS Reagent Program

20301 Century Boulevard Building 6, Suite 200 Germantown, MD 20874 USA

Phone: 240 686 4740 Fax: 301 515 4015 aidsreagent.org

DATA SHEET

Reagent:	U87 CD4+ Cells
Catalog Number:	4031
Lot Number:	110095
Release Category:	C
Provided:	4.6×10^6 cells/ml. Viability is 96%.
Cell Type:	Human astrocytoma (glioblastoma) cells
Propagation Medium:	DMEM, 85%; fetal bovine serum, 15%. Supplement with 300 μ g/ml G418, glutamine, and pen/strep (Note: puromycin-sensitive).
Freeze Medium:	Fetal bovine serum, 90%; DMSO, 10%.
Growth Characteristics:	Cells divide slowly; however, they should not be allowed to become over-confluent. In general, pass cells at 80% confluency and split no more than 1:10. Sensitive to acidic medium.
Sterility:	Negative for mycoplasma, bacteria and fungi.
Description:	U87MG cells stably transduced to express CD4.
Special Characteristics:	U87MG cells (cat# 2188) were stably transduced with the MV7neo-T4 retroviral vector and selected for G418 resistance. Human CD4 expression is directed by the MV7 vector MLV LTR.
	Control cell line for HIV/SIV infections. U87 cells endogenously express the virus coreceptors BoB/GPR1 and Bonzo/STRL33, which can be used by certain SIV and HIV-2 isolates for cell entry. This cell line is puromycin-sensitive.
	Alternate names: U87.CD4

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Contributor:	Dr. HongKui Deng and Dr. Dan Littman.
References:	Björndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, Albert J, Scarlatti G, Littman DR, Fenyo EM. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. <i>J Virol</i> 71 :7478–7487, 1997.
NOTE:	Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: U87.CD4 from Dr. HongKui Deng and Dr. Dan R. Littman." Also include the reference cited above in any publications.
	Patent pending.Scientists at for-profit institutions or who intend commercial use of this reagent must contact the New York University Office of Industrial Liaison at the following email address: abram.goldfinger@nyumc.org
Last Updated	June 22, 2017

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.